Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





ETHYL ACRYLATE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 140-88-5; **Chemical Formula:** CH2 = CHCOOC2H5
OSHA formerly had an 8-hour TWA limit of 25 ppm for ethyl acrylate, with a skin notation. The ACGIH has a TLV-TWA of 5 ppm, a TLV-STEL of 25 ppm, and a skin notation for ethyl acrylate, which is a colorless liquid. The proposed PEL was an 8-hour TWA of 5 ppm and a 15-minute STEL of 25 ppm, with a skin notation; the final rule establishes these limits.
Ethyl acrylate produces irritation of the skin, eyes, mucous membranes, gastrointestinal tract, and respiratory system (Dreisbach 1974/Ex. 1-896). The oral LD(50) in rats fed this substance is 1020 mg/kg, and the 4-hour inhalation LC(50) for these animals ranges between 1000 ppm and 2000 ppm. In rabbits, the dermal LD(50) is 1790 mg/kg (Pozzani, Weil, and Carpenter 1949/Ex. 1-925), and the minimum oral LD(50) is 280 to 420 mg/kg (Treon, Sigmon, Wright, and Kitzmiller 1949/Ex. 1-769). Animal studies also indicate that severe chronic effects may result from exposure to this substance. Rats exposed to levels of 70, 300, or 540 ppm of ethyl acrylate for up to 30 days showed accelerated mortality and pathologic changes in the lungs, liver, and kidneys. In those animals that developed pneumonia, renal and hepatic lesions were also seen. In a parallel study, rats, rabbits and guinea pigs who were subjected to ethyl acrylate concentrations in excess of 75 ppm for 50 seven-hour inhalation periods exhibited pulmonary edema; degenerative changes in the heart, liver, and kidneys; and death (Treon, Sigmon, Wright, and Kitzmiller 1949/ Ex. 1-769). Miller et al. (1980, as cited in ACGIH 1986/Ex. 1-3, p. 240) reported that rats and mice exposed to 75 or 225 ppm, six hours per day for 30 days, developed nasal lesions and other degenerative inflammatory changes in the nasal structure. In other studies, rats and mice administered 100 or 200 mg/kg ethyl acrylate by gavage five times per week for 103 weeks developed inflammation and hyperplasia of the forestomach in addition to squamous cell carcinomas and papillomas in the same area (NTP 1983b, as cited in ACGIH 1986/Ex. 1-3, p. 240). Based on a study by Miller et al. (1980, as cited in ACGIH 1986/Ex. 1-3, p. 240), in which rats and mice exposed to 25 or 75 ppm ethyl acrylate for six hours per day, five days per week for 27 months developed lesions in the nasal cavity even at the lowest dose, the ACGIH (1986/Ex. 1-3, p. 240) concurs with the American Industrial Hygiene Association (1966/Ex. 1-1195) that a 25-ppm limit for ethyl acrylate is too high to prevent irritating effects in exposed humans.
In a study by Nemec and Bauer (1978, as cited in ACGIH 1986/Ex. 1-3, p. 240), human volunteers experienced drowsiness, headache, and nausea after prolonged inhalation exposures at 50 to 75 ppm. Opdyke (1975/Ex. 1-922) reported that the application of a 4-percent concentration of ethyl acrylate produced skin-sensitization reactions in 10 out of 24 volunteers.
NIOSH (Ex. 8-47, Table N6B; Tr. pp. 3-97 to 3-98) believes that a full Section 6(b) rulemaking is needed for this potential occupational carcinogen. A comment from Basic Acrylic Monomer Manufacturers (Ex. 184) urges OSHA not to adopt values still on the ACGIH Notice of Intended Changes. As discussed in Section IV, OSHA is not adopting these limits.
In the final rule, OSHA is establishing an 8-hour TWA of 5 ppm and a 15-minute STEL of 25 ppm for ethyl acrylate; the skin notation is being retained. The Agency concludes that these limits will protect workers from the significant risk of severe eye, nose, and skin irritation associated with exposure to this substance at the levels permitted by OSHA’s former limit. The Agency considers these adverse effects material impairments to health.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue